Literature DB >> 33399856

Characterization of Ebola Virus-Associated Eye Disease.

Allen O Eghrari1, Rachel J Bishop2, Robin D Ross3, Bionca Davis4, Jemma Larbelee5, Fred Amegashie6, Robert F Dolo7, S Grace Prakalapakorn8, Catherine Gaisie7, Catherine Gargu9, Yassah Sosu9, Jennie Sackor9, Precious Z Cooper9, Augustine Wallace9, Ruth Nyain9, Maima Gray9, Famatta Kamara9, Bryn Burkholder1, Christopher J Brady10, Vincent Ray11, Kirstin L Tawse12, Ian Yeung2, James D Neaton4, Elizabeth S Higgs2, H Clifford Lane2, Cavan Reilly4, Michael C Sneller2, Mosoka P Fallah13.   

Abstract

Importance: Survivors of Ebola virus disease (EVD) may experience ocular sequelae. Comparison with antibody-negative individuals from the local population is required to characterize the disease. Objective: To assess features of ophthalmic disease specific to EVD. Design, Setting, and Participants: This baseline cross-sectional analysis of survivors of EVD and their close contacts was conducted within PREVAIL III, a 5-year, longitudinal cohort study. Participants who enrolled at John F. Kennedy Medical Center in Liberia, West Africa from June 2015 to March 2016 were included in this analysis. Close contacts were defined as household members or sex partners of survivors of EVD. Data were analyzed from July 2016 to July 2020. Exposures: All participants, both survivors and close contacts, underwent testing of IgG antibody levels against Ebola virus surface glycoprotein. Main Outcomes and Measures: Ocular symptoms, anterior and posterior ophthalmologic examination findings, and optical coherence tomography images were compared between antibody-positive survivors and antibody-negative close contacts.
Results: A total of 564 antibody-positive survivors (320 [56.7%] female; mean [SD] age, 30.3 [14.0] years) and 635 antibody-negative close contacts (347 [54.6%] female; mean [SD] age, 25.8 [15.5] years) were enrolled in this study. Survivors were more likely to demonstrate color vision deficit (28.9% vs 19.0%, odds ratio [OR], 1.6; 95% CI, 1.2-2.1) and lower intraocular pressure (12.4 vs 13.5 mm Hg; mean difference, -1.2 mm Hg; 95% CI, -1.6 to -0.8 mm Hg) compared with close contacts. Dilated fundus examination revealed a higher percentage of vitreous cells (7.8% vs 0.5%; OR, 16.6; 95% CI, 5.0-55.2) and macular scars (4.6% vs 1.6%; OR, 2.8; 95% CI, 1.4-5.5) in survivors than in close contacts. Uveitis was present in 26.4% of survivors and 12.1% of close contacts (OR, 2.4; 95% CI, 1.8-3.2). Among all participants with uveitis, survivors were more likely than close contacts to have intermediate uveitis (34.2% vs 6.5% of all cases; OR, 7.8; 95% CI, 3.1-19.7) and had thicker mean central subfield thickness on optical coherence tomography (222 vs 212 μm; mean difference, 14.4 μm; 95% CI, 1.9-26.9 μm). Conclusions and Relevance: In this cross-sectional study, survivors of EVD had a distinct spectrum of ocular and neuro-ophthalmologic findings compared with close contacts that potentially require medical and surgical treatment.

Entities:  

Year:  2021        PMID: 33399856     DOI: 10.1001/jamanetworkopen.2020.32216

Source DB:  PubMed          Journal:  JAMA Netw Open        ISSN: 2574-3805


  2 in total

1.  Efficacy and Safety Outcomes of Cataract Surgery in Survivors of Ebola Virus Disease: 12-Month Results From the PREVAIL VII Study.

Authors:  Allen O Eghrari; Jessica G Shantha; Robin D Ross; Collin Van Ryn; Ian Crozier; Brent Hayek; Dan Gradin; Ben Roberts; S Grace Prakalapakorn; Fred Amegashie; Kumar Nishant; Gurcharan Singh; Robert Dolo; John Fankhauser; Bryn Burkholder; James Pettitt; Robin Gross; Tyler Brady; Bonnie Dighero-Kemp; Cavan Reilly; Lisa Hensley; Elizabeth Higgs; Steven Yeh; Rachel J Bishop
Journal:  Transl Vis Sci Technol       Date:  2021-01-25       Impact factor: 3.283

2.  Dose-Dependent Response to Infection with Ebola Virus in the Ferret Model and Evidence of Viral Evolution in the Eye.

Authors:  Robert J Watson; Julia Tree; Susan A Fotheringham; Yper Hall; Xiaofeng Dong; Kimberley Steeds; Jade Gouriet; Francisco J Salguero; Christopher Burton; James Pitman; Linda Easterbrook; Kevin S Richards; Jane Burton; Kevin Bewley; Christine Bruce; Julian A Hiscox; Miles W Carroll; Simon G P Funnell
Journal:  J Virol       Date:  2021-09-29       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.